BenzingaAugust 13, 2026 at 7:25 AM NY2 Months Ago
JP Morgan Maintains Overweight on CytomX Therapeutics, Lowers Price Target to $11
JP Morgan analyst Anupam Rama maintains CytomX Therapeutics (NASDAQ:CTMX) with a Overweight and lowers the price target from $12 to $11.
What This Story Means
Claude is explaining the story in plain words…
Read the Full Story at the Source
The summary here comes from the news provider; the rest of the article lives on the publisher's site: Benzinga
